This trial is evaluating whether Brentuximab Vedotin will improve 2 primary outcomes and 13 secondary outcomes in patients with Hodgkin Disease. Measurement will happen over the course of 24 weeks (end of treatment).
This trial requires 43 total participants across 2 different treatment groups
This trial involves 2 different treatments. Brentuximab Vedotin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
The only signs of hodgkin disease are pain in the lymph nodes in the neck, chest, or armpits. An enlarged spleen or low white blood cell count may be present in some patients. The signs usually begin with a person in their 45s.\n
Between 11 and 19.2 per 100,000 Caucasian males and 10.6 and 8.5 per 100,000 Caucasian females develop Hodgkin disease each year. This has resulted in the average cumulative lifetime risk of developing Hodgkin disease being 2.14% (males) and 1.88% (females). It is estimated that every year, more than 1 in 1000 men and women are diagnosed with Hodgkin disease in the United States.
Brentuximab vedotin can produce complete tumor response in patients with relapsed Hodgkin lymphoma. There was little evidence for remission or progression-free survival in subjects with a complete response (CR).
Currently, there are very few new treatments that have been developed or tested for patients with hodgkin disease. More research is needed to develop novel strategies for treatment.
HD is a rare disease of the blood and is characterized by a progressive enlargement and subsequent obstruction of the small tributary veins of the lymph nodes. It is the fifth most common cause of primary mediastinal lymphadenopathy and one of the most common diagnoses in Hodgkin disease from America.\n
Although no cures for Hodgkin disease exist, a number of targeted treatments are being developed and studied, such as rituximab, which has had some success in reducing symptoms in some cases. Results from a recent paper suggest that Hodgkin lymphoma may, in principle, be treated, at least in some cases, with targeted therapies specifically designed and developed to fight the illness.
In a real-life setting, the most common treatments for HD are chemotherapy, surgery, and splenectomy; in this study, radiation was the treatment with the highest percentage of use.
Most cases of HD do not develop from a viral infection. HD remains an incurable condition, and patients should, therefore, be aware that the disease may be a hereditary condition that affects more than half of cases.
Hodgkin disease is a very serious condition with a high incidence of death, and the prognosis is worse for patients who are young (aged 15-28 years) and Caucasian. However, this patient group is often overlooked due to a high rate of confusion due to similar symptom presentations, and in many cases the clinical and radiographic features are nonspecific, hence the delay in diagnosis and treatment.
Brentuximab vedotin is often administered at full dose, instead of the standard 50 mg/m2 (maximum 250 mg/m of body surface area) dose, to reduce drug-related toxicities. This may be justified for patients who cannot tolerate the full dose due to tumor load, or if tumors are small and would not be exposed to the full dose due to uncertainties in dosing. However, these decisions are complex and require individualized medical knowledge and discussion.
In patients with relapsed indolent CD30(+) Hodgkin lymphoma (HL), brentuximab vedotin was more effective than a placebo in terms of overall survival and progression-free survival.
There are many different routes to developing HD: genetic predisposition is common. It is a disease with relatively good prospects of cure if found early.